Atopic Dermatitis Treatment Landscape
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.
Incidence of Atopic Dermatitis
Location, Location, Location
Assessing the Severity of AD Comparing EASI, SCORAD, and IGA
Patient-Reported Burden of AD
Impact of AD on Quality of Life
Impact of AD on Mental Health
Burden of AD
Novel Treatments for AD
CHRONOS: Dupilumab for the Management of Moderate-to-Severe AD
CHRONOS: Dupilumab Efficacy
Dupilumab Increased Incidence of Conjunctivitis
Lebrikizumab
Lebrikizumab Efficacy: Results From TREBLE
Tralokinumab Efficacy
Nemolizumab: IL-31R Targeting Antibody
Nemolizumab Efficacy
JAK Inhibitors
Novel Topical Agents: Crisaborole
Topical JAK Inhibitors
Other Agents in Development for AD
Is the Patient a Candidate for Systemic Treatment
Take-Home Messages